Titlebook: Infectious Complications in Biologic and Targeted Therapies; Carlos Cervera,Jose Maria Aguado Book 2022 The Editor(s) (if applicable) and

禁令

CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4ver the past 20?years, many monoclonal antibodies targeting these antigens have been developed and introduced into clinical practice. Many of them are used successfully for the treatment of leukemia, lymphoma, multiple myeloma, and systemic autoimmune diseases (e.g. systemic ., Sjogren’s syndrome) b

嚴厲批評

Customary

Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agentsnd associated signaling pathways among cancer patients and to suggest recommendations..Anti-epidermal growth factor receptor monoclonal antibodies (cetuximab and panitumumab) are associated with an increased risk of neutropenia. They may also induce papulopustular rash which may predispose to second

采納

Interleukin-1 Targeted Agentsk of infectious complications associated with the use of interleukin-1 (IL-1) targeted therapy..: A narrative review was undertaken utilizing computer-based MEDLINE searches for each IL-1 targeting agent. Literature review was focused on available meta-analysis, randomized controlled trials (RCT), a

巨頭

Interleukin-6 Targeted Agentseceptor may result in severe and potentially life-threatening infections with significant discrepancy in both clinical and laboratory markers. Current evidence on the infection risk associated with the use of IL-6 or IL-6R-targeted agents consists mostly of studies including patients treated for a c

抑制

aggravate

definition

Immune Checkpoint Inhibitorsecificity and self-tolerance. The two major families of checkpoint inhibitors target the CTLA-4/B7s and the PD-1/PD-L1 axis. Inhibition of either of these two pathways intends to enhance the antitumor activity of lymphocytes. The risk of infections associated with checkpoint inhibition can be explai

Little

α4-Integrin (and Other Leukocyte Integrin)-Targeting Agentsruitment of leukocytes from the vasculature to the tissues and are used as therapeutic targets to modulate inflammation. The monoclonal antibody natalizumab targets the α4 subunit of α4β1 and α4β7 integrins, implicated in the entry of lymphocytes in the central nervous system (CNS) and the gut mucos

Eulogy